ABL1 siRNA Set I(A03-911)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :ABL1 is a pool of three individual synthetic siRNA duplexes designed to knock-down human ABL1 mRNA expression. Each siRNA is 19-25 bases in length.
Specificity :ABL1 siRNAs are designed to specifically knock-down human ABL1 expression.
Formulation :The siRNAs are supplied as a lyophilized powder and shipped at room temperature.
Reconstitution Protocol :Briefly centrifuge the tubes (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend the siRNA in 50 ul of DEPC-treated water (supplied by researcher), which results in a 1x stock solution (10 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.
Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.
Format :Lyophilized powder
Gene Aliases :ABL; JTK7; p150; c-ABL; v-abl
Scientific Background :ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of ABL protein is negatively regulated by its SH3 domain and deletion of the SH3 domain turns ABL1 into an oncogene (1). Translocation and head-to-tail fusion of the BCR and ABL1 genes is present in many cases of chronic myelogeneous leukemia (2). The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDK1-mediated phosphorylation, suggesting a cell cycle function for ABL1.
1. Barila, D. et al : An intramolecular SH3-domain interaction regulates c-Abl activity. Nature Genet. 18: 280-282, 1998.
2. Goldman, J M. et al : Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Eng. J. Med. 344: 1084-1086, 2001.
Product Sheets (By Lot #) :
Research Areas :Cancer, Cell Cycle, Cytoplasmic Tyrosine Kinases, Inflammation, Invasion/Metastasis, Neurobiology, Cancer, Neurobiology, Inflammation, Cell Cycle, Invasion/Metastasis, Cytoplasmic Tyrosine Kinases